Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia

Background Tisagenlecleucel, an anti-CD19 chimeric antigen receptor T cell therapy, has demonstrated efficacy in children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) in two multicenter phase 2 trials (ClinicalTrials.gov, NCT02435849 (ELIANA) and NCT02228096...

Full description

Bibliographic Details
Main Authors: Rajen Mody, Carl H June, Michael R Verneris, Stephan A Grupp, Keith J August, André Baruchel, Shannon L Maude, Peter Bader, Stella M Davies, John E Levine, Michael A Pulsipher, Andrew C Dietz, Susana Rives, G Douglas Myers, Jochen Buechner, Theodore W Laetsch, Henrique Bittencourt, Michael W Boyer, Barbara De Moerloose, Muna Qayed, Christine L Phillips, Timothy A Driscoll, Krysta Schlis, Patricia A Wood, Lan Yi, Mimi Leung, Lamis K Eldjerou
Format: Article
Language:English
Published: BMJ Publishing Group 2021-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/8/e002287.full

Internet

https://jitc.bmj.com/content/9/8/e002287.full

Similar Items